GSK
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
December 16, 2025Regulatory Affairs, Research and Development Asthma & COPD, GSK
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) …
Ochre Bio appoints Quin Wills as CEO to lead next phase of liver therapeutics development
June 30, 2025Research and Development Boehringer Ingelheim, CEO, GSK, Hepatology, Ochre Bio, RNA therapeutics, chronic liver disease, clinical genomics
Oxford-based biotechnology company Ochre Bio has announced the appointment of Quin Wills as CEO. As co-founder of the company and …
Multiple myeloma treatment approved in Japan
May 21, 2025Market Access, Research and Development, Sales and Marketing GSK, Japan, Oncology, Orphan Drug Designation (ODD), multiple myeloma
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and Welfare for the treatment of …
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
August 5, 2024Research and Development GSK, Oncology, Reproductive health, endometrial cancer
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel (chemotherapy) …
ViiV Healthcare shares data for two-drug regimen for HIV-1 maintenance therapy
July 23, 2024Research and Development GSK, HIV, HIV/AIDS, ViiV Healthcare, maintenance therapy
GSK has announced that ViiV Healthcare, a specialist HIV company predominantly owned by GSK with Pfizer and Shionogi as shareholders, …
GSK’s application for Blenrep for MM treatment accepted for EMA review
July 19, 2024Medical Communications Blenrep, EMA, GSK, Oncology
GSK has announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for Blenrep (belantamab mafodotin) …
GSK and CureVac to restructure collaboration into licensing agreement
July 3, 2024Sales and Marketing CureVac, GSK, Immunology, License Agreement, collaboration
GSK and CureVac have announced that they have restructured their existing collaboration into a license agreement, which is intended to …
GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment
June 24, 2024Medical Communications EMA, GSK, Jemperli, Oncology, endometrial cancer
GSK has announced that the European Medicines Agency (EMA) has accepted the application to expand the use of Jemperli (dostarlimab) …
GSK’s Arexvy vaccine approved by FDA for RSV prevention in adult patients
June 10, 2024Medical Communications FDA, GSK, Immunology, Vaccine
GSK has announced that the US Food and Drug Administration (FDA) has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) …
GSK shares positive results from phase 3 asthma trials
May 21, 2024Research and Development Asthma & COPD, GSK, asthma, clinical trial
GSK has announced positive headline results from its phase 3 SWIFT-1 and SWIFT-2 trials, which evaluated the safety and efficacy …
GSK pledges £45m to Fleming Initiative to fight AMR
May 16, 2024Research and Development AMR, Fleming Initiative, GSK, Microbiology, funding
GSK has announced that it has pledged £45m to the Fleming Initiative, becoming the first founding partner of the innovative …
GSK’s Jemperli accepted for FDA review for endometrial cancer treatment
April 24, 2024Medical Communications FDA, GSK, Oncology, endometrial cancer, sBLA
GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for …
GSK shares results from phase 3 trial for gonorrhoea treatment
April 18, 2024Research and Development GSK, Reproductive health, clinical trial, gonorrhoea, sexual health
GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential first-in-class oral antibiotic for the …
GSK’s meningococcal vaccine candidate accepted for FDA review
April 16, 2024Medical Communications FDA, GSK, Immunology, meningococcal
GSK has announced that the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) …
GSK shares data from phase 3 trial for Jemperli combinations for endometrial cancer treatment
March 18, 2024Research and Development GSK, Jemperli, Oncology, clinical trial, endometrial cancer, women's health
GSK has announced positive results from part 1 and part 2 of its RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial for Jemperli (dostarlimab) …
